Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about Amgen blood cell disorder drug meets primary goal in phase 3 trial
Amgen announced that the randomized, double-blind, placebo-controlled Phase 3 Aranesp® (darbepoetin alfa) ARCADE trial met its primary endpoint of reducing the incidence of red blood cell transfusions in anemic patients with low and intermediate-1 risk Myelodysplastic Syndrome (MDS) at the end of the blinded 25-week study period. Aranesp also significantly improved erythroid response, a key measure of the formation of new red blood cells. Detailed results will be submitted to a future medical conference and for publication.
- Read more about Kindred Biosciences seeks US FDA approval for Zimeta to treat pyrexia in horses
Kindred Biosciences seeks US FDA approval for Zimeta to treat pyrexia in horseKindred Biosciences, Inc., announced the submission to FDA of the Effectiveness Technical Section of the New Animal Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).
- Read more about Merck receives complete response letter from U.S. FDA for ZETIA and VYTORIN
Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding Merck's Supplemental New Drug Applications for ZETIA® and VYTORIN® for the reduction of the risk of cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina, or need for revascularization) in patients with coronary heart disease.
- Read more about Wenzel Spine announces FDA clearance to launch VariLift®-LX
Wenzel Spine, Inc., a pioneer medical device company focused on providing minimally invasive, stand-alone alternatives to traditional spinal fusion, announced today that it received clearance from the U.S. Food and Drug Administration (FDA) to market VariLift®-LX as an interbody fusion device for stand-alone use in the lumbar spine.
- Read more about Green tea compound may help combat rheumatoid arthritis
A compound in green tea may offer a potential new approach to combating the joint pain, inflammation and tissue damage caused by rheumatoid arthritis.
- Read more about Indian pharma companies target West African market
As India's pharmaceutical companies continue to look for greener pastures for growth, the 70 participants in the two-day IPHEX Africa trade exhibition in the Nigerian commercial capital of Lagos will be aiming to increase their exports to western Africa where they see a significant growth potential.
- Read more about Oral bacteria linked to higher stroke risk: Study
Oral bacteria may be involved in several kinds of stroke, including brain hemorrhages and strokes that lead to dementia, says a new study.
- Read more about Bury your BP in the kitchen
Don't let the high blood pressure that you have been diagnosed with scare you out of your wits. It is not exactly a disease, but only a warning sign that the food you have been eating and the lifestyle you have been leading have clogged your blood vessels and your heart is having to exert extra pressure to keep blood moving through it.

(adsbygoogle = window.adsbygoogle || []).push({});
- Read more about Brain neurons linked to depression identified
Paving the way for new depression treatments, researchers have discovered the first-ever connection between vulnerability to depression and a type of brain cells called noradrenergic neurons.
- Read more about 1 In 7 Indian drugs revealed as sub-standard
Substandard medicines could be three times more prevalent than the government says, two new studies show. These data have serious implications on health in a country where 58.2 percent of the total health expenditure is an out-of-pocket cost burden on people, according to the World Health Organization, and where medicines alone account for between 70 percent and 77 percent of health spending.